From the Systems Biology Center, Biomedical Research Foundation, Academy of Athens, Greece (A.V.).
FIZ Karlsruhe - Leibniz-Institut für Informationsinfrastruktur, Eggenstein-Leopoldshafen, Germany (D.H., F.B.).
Hypertension. 2021 Apr;77(4):1029-1035. doi: 10.1161/HYPERTENSIONAHA.120.16340. Epub 2021 Feb 15.
The General Data Protection Regulation (GDPR) became binding law in the European Union Member States in 2018, as a step toward harmonizing personal data protection legislation in the European Union. The Regulation governs almost all types of personal data processing, hence, also, those pertaining to biomedical research. The purpose of this article is to highlight the main practical issues related to data and biological sample sharing that biomedical researchers face regularly, and to specify how these are addressed in the context of GDPR, after consulting with ethics/legal experts. We identify areas in which clarifications of the GDPR are needed, particularly those related to consent requirements by study participants. Amendments should target the following: (1) restricting exceptions based on national laws and increasing harmonization, (2) confirming the concept of broad consent, and (3) defining a roadmap for secondary use of data. These changes will be achieved by acknowledged learned societies in the field taking the lead in preparing a document giving guidance for the optimal interpretation of the GDPR, which will be finalized following a period of commenting by a broad multistakeholder audience. In parallel, promoting engagement and education of the public in the relevant issues (such as different consent types or residual risk for re-identification), on both local/national and international levels, is considered critical for advancement. We hope that this article will open this broad discussion involving all major stakeholders, toward optimizing the GDPR and allowing a harmonized transnational research approach.
《通用数据保护条例》(GDPR)于 2018 年成为欧盟成员国的具有约束力的法律,旨在协调欧盟个人数据保护立法。该法规几乎涵盖了所有类型的个人数据处理,因此也涵盖了生物医学研究相关的数据处理。本文的目的是突出强调生物医学研究人员经常面临的与数据和生物样本共享相关的主要实际问题,并在咨询伦理/法律专家后,具体说明这些问题在 GDPR 背景下是如何解决的。我们确定了需要澄清 GDPR 的领域,特别是与研究参与者的同意要求有关的领域。修正案应针对以下方面:(1)限制基于国家法律的例外情况并增加协调,(2)确认广义同意的概念,以及(3)定义数据二次使用的路线图。这些变化将由该领域公认的专业学会牵头制定一份文件,为 GDPR 的最佳解释提供指导,该文件将在经过广泛的利益相关者群体的评论期后定稿。同时,在地方/国家和国际层面上,促进公众对相关问题(如不同的同意类型或重新识别的剩余风险)的参与和教育被认为是至关重要的,这将有助于推动研究的发展。我们希望本文能够开启涉及所有主要利益相关者的广泛讨论,以优化 GDPR 并允许协调一致的跨国研究方法。